Rob Etherington is the President and Chief Executive officer at Clene Nanomedicine.  Prior to joining Clene as CEO, Mr. Etherington worked for Actelion Pharmaceuticals. He initially joined Actelion as founding Director of Marketing in 2000, the same year the company went public, and went on to hold various roles of increasing responsibility. Mr. Etherington served as Chair of the U.S. Commercial Strategic team where he was responsible for five marketed drugs. Prior to Actelion, Mr. Etherington began his pharmaceutical career with a number of sales and marketing roles at Parke-Davis, a division of Pfizer, culminating in a Team Leader position that oversaw the drug Lipitor. Mr. Etherington obtained MBA from Brigham Young University.